10-Q: Cryo-Cell International Reports Q1 2026 Financials

Cryo-Cell International, Inc. reported a decrease in revenue for the first quarter of fiscal year 2026, primarily due to lower public banking revenue and a slight dip in processing and storage fees, while SG&A expenses increased due to legal fees.

Summary

• Cryo-Cell International reported total revenue of $7,683,117 for the three months ended February 28, 2026, a decrease of 4% compared to $7,968,880 in the same period last year.
• Processing and storage fees, the company's primary revenue source, decreased by 3% to $7,643,113, attributed to a 16% decrease in new domestic cord blood specimens processed, partially offset by a 3% decrease in annual storage fees.
• Product revenue increased by 84% to $38,594, while public cord blood banking revenue significantly decreased by 98% to $1,410.
• Cost of sales decreased by 17% to $1,656,488, largely due to lower public banking costs.
• Selling, general, and administrative (SG&A) expenses increased by 8% to $5,011,847, primarily driven by a significant increase in legal fees and expert opinion expenses related to the Duke dispute.
• Net income for the quarter was $47,108, a substantial decrease from $282,855 in the prior year's comparable period.
• The company's cash and cash equivalents decreased to $249,672 as of February 28, 2026, from $319,031 as of November 30, 2025.
• The company is facing a delisting warning from NYSE American due to non-compliance with continued listing standards, with a plan of compliance submitted.
• A significant legal dispute with Duke University is ongoing, involving an arbitration demand by Cryo-Cell for fraudulent inducement and breach of contract, and counterclaims by Duke.
• Duke University has issued a notice of termination for the License Agreement, effective May 17, 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to declining revenues, significantly reduced net income, increased legal expenses, and the serious risk of delisting from the NYSE American, compounded by a major legal dispute with a key partner.

Positives

• Product revenue saw a significant increase of 84% to $38,594.
• Cost of sales decreased by 17% to $1,656,488, indicating improved cost management in certain areas.
• The company continues to maintain a 100% viability rate of its specimens upon thaw for therapeutic use.
• The company has a strong history as the world's first private cord blood bank and holds AABB and FACT accreditations.
• The company has a substantial amount of deferred revenue ($61.46 million), representing future recognized income.

Negatives

• Total revenue decreased by 4% to $7,683,117.
• Processing and storage fees, the core revenue stream, decreased by 3%.
• Public cord blood banking revenue experienced a drastic 98% decrease.
• Selling, general, and administrative expenses increased by 8% to $5,011,847, largely due to increased legal costs.
• Net income decreased significantly by 83% to $47,108.
• Cash and cash equivalents decreased by approximately 22% to $249,672.
• The company received a notice of non-compliance with NYSE American continued listing standards.
• A major legal dispute with Duke University is ongoing, with Duke issuing a notice of termination for their license agreement.
• The company's ability to expand into new business units (infusion clinics, biopharmaceutical manufacturing) is unlikely due to the Duke dispute.
• The proposed spinoff of Celle Corp. is on hold.

Risks

• The company is not in compliance with NYSE American continued listing standards and faces potential delisting.
• The ongoing arbitration with Duke University and Duke's notice of termination of the license agreement pose significant legal and operational risks.
• The company's ability to commercialize rights licensed under the Duke Agreement, treat patients, or spin off Celle Corp. is uncertain.
• Increased competition in the stem cell storage market, particularly from public cord blood banks.
• Potential decrease in demand for umbilical cord blood stem cell storage or a slowdown in annual storage fee payments.
• Risks associated with international activities, including local business laws and practices.
• Technological or medical breakthroughs that could render stem cell preservation obsolete.
• Material failure or malfunction in storage facilities, or natural disasters affecting stored specimens.
• Adverse results from litigation, particularly concerning intellectual property.
• Inability to obtain additional debt or equity financing on favorable terms, or at all, which could impact operations and compliance efforts.

Future Outlook

The company anticipates that its cash and cash equivalents, marketable securities, and cash flows from operations, along with external capital sources, will be sufficient to fund its known cash needs for at least the next 12 months. However, future funding needs related to the Duke License Agreement are currently unpredictable due to the ongoing dispute. The company may require additional capital for planned infusion clinics, clinical trials, biopharmaceutical manufacturing, and capital expenditures if the Duke dispute resolution necessitates it. Without resolution, further investments in Duke-related activities are not anticipated. The opening of the Cryo-Cell Institute for Cellular Therapies and the spinoff of Celle Corp. remain on hold.

Management Comments

• Management believes that the Company's payment plans do not include significant financing components.
• Management believes that the resolution of the Duke counterclaims should not have a material adverse effect on the Company's business, consolidated financial position or results of operations.
• Management does not expect its disclosure controls and internal controls to prevent all error and all fraud, acknowledging the inherent limitations of control systems.
• Management believes that its cash and cash equivalents, marketable securities and cash flows from operation, together with external sources of capital will be sufficient to fund its known cash needs for at least the next 12 months.

Industry Context

StockSavvy.ai notes that Cryo-Cell International's performance in this quarter reflects challenges common in the specialized biotech and life sciences sector, particularly those involving complex licensing agreements and regulatory hurdles. The decrease in public banking revenue and the increase in legal expenses highlight the financial strain that protracted legal disputes can place on companies in this industry, potentially impacting their ability to pursue growth initiatives and maintain exchange listing standards.

Comparison to Industry Standards

• The company's revenue decrease of 4% in Q1 2026, while concerning, needs to be compared against the broader biotech and cord blood banking industry's growth rates for the same period. Industry benchmarks for revenue growth in this niche sector can vary significantly based on R&D pipelines, market penetration, and competitive landscapes.
• The significant increase in SG&A expenses, particularly legal fees, is a critical factor. In the biotech and pharmaceutical industries, legal expenses related to intellectual property disputes, licensing agreements, and regulatory challenges are common. However, an 8% increase driven by legal costs, especially in the context of a revenue decline, is a red flag that warrants close monitoring against industry averages for companies of similar size and stage.
• The company's net income decline of 83% is substantial. While specific industry benchmarks for net income margins in cord blood banking are not readily available, a sharp decrease like this suggests significant operational or financial pressures that may be out of step with industry peers who are successfully navigating market conditions or have more stable revenue streams.
• The company's struggle to maintain NYSE American listing standards is a significant concern. Many smaller biotech and life sciences companies face delisting risks if they cannot meet financial or market capitalization requirements. This contrasts with larger, more established players in the sector who typically have more robust financial performance and market presence.

Corporate Governance

Legal Proceedings

• Demand for arbitration filed against Duke University alleging fraudulent inducement and breach of contract, seeking damages exceeding $100 million.
• Duke University has filed counterclaims for breach of license agreement and indemnity.
• Duke University has issued a notice of termination of the License Agreement, effective May 17, 2025.
• The company is subject to other proceedings, lawsuits, contract disputes, and claims in the normal course of business.

Stakeholder Impact

• Shareholders: Potential for share price decline due to delisting risk and negative financial performance. Dilution risk from potential future equity financing.
• Creditors: The company's liquidity and ability to service debt may be impacted by financial performance and potential delisting.
• Employees: Uncertainty regarding future operations and potential impact on employment due to legal disputes and financial challenges.
• Business Partners (e.g., Duke University): The termination of the license agreement with Duke University significantly impacts future business development and operations.

Next Steps

• The company has submitted a plan of compliance to NYSE American to regain compliance with continued listing standards.
• A final hearing on the Company's claims and Duke's counterclaims is scheduled for late April 2026.
• The company will continue to monitor its financial condition and operational performance.
• The company will assess the impact of the Duke dispute resolution on its future funding needs and strategic initiatives.

Key Dates

Recommendation

The company is facing significant headwinds including declining revenues, a sharp drop in net income, increased legal expenses, and a critical risk of delisting from the NYSE American. The ongoing, complex legal dispute with Duke University, which has resulted in a termination notice for their license agreement, introduces substantial uncertainty and operational disruption. These factors collectively suggest a deteriorating financial and operational outlook, making it prudent for investors to consider selling their holdings.

Keywords

Cryo-Cell International, 10-Q Filing, Quarterly Report, Stem Cell Storage, Cord Blood Banking, Umbilical Cord Blood, Cryopreservation, Biopharmaceutical, Duke University, Legal Proceedings, NYSE American, Financial Results